- Presentations
- 5
- Markets
- 1
Jakafi XR is a brand of Ruxolitinib marketed by Incyte, with 5 presentations listed and registered in United States. Each presentation below has its own page with packs, documents and availability for export supply from India.
- Active ingredient (INN)
- Ruxolitinib
- Brand owner
- Incyte
- Registered in
- United States
- Strengths and forms
- 11 mg extended-release tablet, 22 mg extended-release tablet, 33 mg extended-release tablet, 44 mg extended-release tablet, 55 mg extended-release tablet
All presentations
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Jakafi XR 11 mg extended-release tabletOral | Incyte | US FDA | Available on request |
| Jakafi XR 22 mg extended-release tabletOral | Incyte | US FDA | Available on request |
| Jakafi XR 33 mg extended-release tabletOral | Incyte | US FDA | Available on request |
| Jakafi XR 44 mg extended-release tabletOral | Incyte | US FDA | Available on request |
| Jakafi XR 55 mg extended-release tabletOral | Incyte | US FDA | Available on request |
Equivalent brands
Other brands of Ruxolitinib.
Brand names and trademarks belong to their owners and are used only to identify products.
Request Jakafi XR
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.